EudraGMP Homepage      
 
 
MIA | GMP | API REG | WDA | GDP | Sites Help
Tue 10 Nov 2026 18:38:29 BST
GMP Compliance Menu 
Search
GMP Certificates
Non-Compliance Report


Print Preview
                  
Print Preview (Short version)
                  
Back To Search

 

Regierungspraesidium Tuebingen

CERTIFICATE NUMBER: DE_BW_01_GMP_2026_0041

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1) , (2)

Part 1

Issued following an inspection in accordance with
Art. 94(1) of Regulation (EU) 2019/6 as amended

The competent authority of Germany confirms the following:

The manufacturer: Losan Pharma GmbH

Site address: Otto-Hahn-Strasse 13, Neuenburg Am Rhein, 79395, Germany

OMS Organisation Id. / OMS Location Id.: ORG-100004326 / LOC-100002524


Has been inspected under the national inspection programme in connection with manufacturing authorisation no.  DE_BW_01_MIA_2026_0007  in accordance with Art. 88 of Regulation (EU) 2019/6.


From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on  2025-12-11 , it is considered that it complies with:

  • The principles and guidelines of Good Manufacturing Practice laid down in Directive 91/412/EEC. (3)  

  • This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (https://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.

     The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

    __________________________________________________________________________________________________________________________
    (1) The certificate referred to in paragraph Art. 80(5) of Directive 2001/82/ECis also applicable to importers.
    (2) Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.
    (3) These requirements fulfil the GMP recommendations of WHO.

    Part 2

    Veterinary Medicinal Products

    1  MANUFACTURING OPERATIONS
    1.2  Non-sterile products
       1.2.1  Non-sterile products (processing operations for the following dosage forms)
               1.2.1.1  Capsules, hard shell
               1.2.1.6  Liquids for internal use
               1.2.1.8  Other solid dosage forms
               1.2.1.12  Suppositories
               1.2.1.13  Tablets
       1.2.2  Batch certification
    1.5  Packaging
       1.5.1  Primary Packaging
               1.5.1.1  Capsules, hard shell
               1.5.1.6  Liquids for internal use
               1.5.1.8  Other solid dosage forms
               1.5.1.12  Suppositories
               1.5.1.13  Tablets
       1.5.2  Secondary packaging
    1.6  Quality control testing
       1.6.3  Chemical/Physical

    2  IMPORTATION OF MEDICINAL PRODUCTS
    2.1  Quality control testing of imported medicinal products
       2.1.3  Chemical/Physical
    2.2  Batch certification of imported medicinal products
       2.2.2  Non-sterile products
    2.3  Other importation activities
       2.3.1  Site of physical importation

    Clarifying remarks (for public users):
    The authorisation is based on the floor plans in document BER_00504 Betriebsstätte Neuenburg Campus, version 2 dated 28 November 2025. The company runs an external storage area and an archive at the following address Industriestraße 4, 79258 Hartheim. Authorised manufacturing does NOT cover blood products, immunological products, cell therapy products, gene therapy products, medicinal products for use in in-vivo diagnosis by means of marker genes, biotechnology products, radiopharmaceuticals and human extracted products. 1.2.1.8 & 1.5.1.8 Other solid dosage forms: powders, granules or pellets. Tablets include coated tablets and effervescent tablets.

     

     



     
     
     
         
     
     
     
     
    The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please click here to get list of NCA's.

    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI.

    Documents issued by UK authorities up to and including 31 December 2020 remain available for consultation in EudraGMDP. However, they are no longer included or updated from 1 January 2021, with the exception of the documents pertaining to sites located in Northern Ireland.

    [EMA © 2014. EudraGMDP 6.5.4.8 build 2026/01/16 09:45]